Orthopedic developer NovoSource said this week it will be liquidating its corporate assets through a court-ordered auction some time in late spring.
The Dayton, Ohio-based medical device maker’s primary products were the NovoKnee total knee system and the NovoHip total hip system.
NovoSource offers a posterior stabilized option for its NovoKnee femoral components, as well as a cruciate retaining design. Its posterior stabilized, cruciate retaining and ultra congruent highly cross linked polyethylene knee inserts are available in 9mm to 18mm sizes in 2mm increments, the company said.
The company’s NovoHip uses a titanium plasma spray cementless tapered stem with 21 different size variations and offered in multiple shell configurations.
Assets to be offered in the sale include all intellectual property, inventory, tooling, design history files as well as regulatory clearances, trademarks, copyrights, ERP system and servers and warehouse equipment and furniture, with the knee and hip implant inventory valued at over $3 million, according to a press release.
The company has not yet decided on a date for the sale.
